Belpointe Asset Management LLC Makes New $50,000 Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Belpointe Asset Management LLC acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Rating) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 872 shares of the biopharmaceutical company’s stock, valued at approximately $50,000.

Other large investors also recently modified their holdings of the company. Advisory Research Inc. grew its holdings in Halozyme Therapeutics by 6.6% during the 3rd quarter. Advisory Research Inc. now owns 37,915 shares of the biopharmaceutical company’s stock worth $1,499,000 after acquiring an additional 2,360 shares during the period. ProShare Advisors LLC increased its holdings in Halozyme Therapeutics by 1.2% in the third quarter. ProShare Advisors LLC now owns 36,252 shares of the biopharmaceutical company’s stock worth $1,434,000 after purchasing an additional 423 shares in the last quarter. TD Asset Management Inc acquired a new position in Halozyme Therapeutics in the fourth quarter valued at approximately $10,406,000. Point72 Asset Management L.P. bought a new position in shares of Halozyme Therapeutics during the 3rd quarter worth approximately $12,014,000. Finally, Resources Investment Advisors LLC. grew its position in shares of Halozyme Therapeutics by 12.2% during the 3rd quarter. Resources Investment Advisors LLC. now owns 6,466 shares of the biopharmaceutical company’s stock worth $256,000 after buying an additional 701 shares during the period. 96.32% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on HALO. StockNews.com started coverage on shares of Halozyme Therapeutics in a research note on Thursday, May 18th. They set a “hold” rating on the stock. JMP Securities restated a “market outperform” rating and issued a $66.00 target price (up from $62.00) on shares of Halozyme Therapeutics in a research note on Wednesday, February 22nd. Piper Sandler raised Halozyme Therapeutics from a “neutral” rating to an “overweight” rating and set a $46.00 price target on the stock in a research note on Wednesday, May 10th. SVB Leerink cut Halozyme Therapeutics from an “outperform” rating to a “market perform” rating and set a $42.00 price objective for the company. in a research note on Thursday, March 16th. Finally, Wells Fargo & Company lowered their target price on Halozyme Therapeutics from $65.00 to $55.00 and set an “overweight” rating on the stock in a research report on Thursday, March 16th. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $55.30.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, March 1st. The shares were sold at an average price of $47.71, for a total transaction of $477,100.00. Following the transaction, the director now owns 39,045 shares of the company’s stock, valued at approximately $1,862,836.95. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In the last ninety days, insiders sold 50,000 shares of company stock valued at $2,214,600. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Trading Down 2.8 %

NASDAQ HALO opened at $34.01 on Wednesday. The company has a current ratio of 6.69, a quick ratio of 5.52 and a debt-to-equity ratio of 22.69. The business has a fifty day simple moving average of $34.69 and a 200 day simple moving average of $46.16. Halozyme Therapeutics, Inc. has a 12 month low of $29.85 and a 12 month high of $59.46. The firm has a market capitalization of $4.48 billion, a P/E ratio of 25.96, a PEG ratio of 0.54 and a beta of 1.21.

Halozyme Therapeutics (NASDAQ:HALO – Get Rating) last posted its earnings results on Tuesday, February 21st. The biopharmaceutical company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.01. Halozyme Therapeutics had a net margin of 25.76% and a return on equity of 184.32%. The firm had revenue of $181.50 million during the quarter, compared to analyst estimates of $186.07 million. On average, analysts predict that Halozyme Therapeutics, Inc. will post 2.4 EPS for the current fiscal year.

Halozyme Therapeutics Profile

(Get Rating)

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.